作者:Matthew J. Belousoff、Hari Venugopal、Alexander Wright、Samuel Seoner、Isabella Stuart、Chris Stubenrauch、Rebecca S. Bamert、David W. Lupton、Trevor Lithgow
DOI:10.1002/cmdc.201900042
日期:2019.3.5
drug design approaches. In this study we exploit common structural features present in linezolid-resistant forms of both methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) to redesign the antibiotic. Enabled by rapid and facile cryoEM structures, this process has identified (S)-2,2-dichloro-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide
虽然核糖体是抗生素的常见靶标,但晶体学挑战可能会阻碍使用基于结构的药物设计方法开发新的生物活性物质。在这项研究中,我们利用耐甲氧西林金黄色葡萄球菌(MRSA)和耐万古霉素肠球菌(VRE)的利奈唑胺抗药性形式的常见结构特征来重新设计抗生素。借助快速而便捷的cryoEM结构,该过程已确定了(S)-2,2-二氯-N-(((3-(3-氟-4-吗啉代苯基)-2-氧杂恶唑烷-5-基)甲基)乙酰胺( LZD-5)和(S)-2-氯-N-((3-(3-氟-3-吗啉代苯基)-2-氧代恶唑啉丁-5-基)甲基)乙酰胺(LZD-6),它们可抑制核糖体耐利奈唑胺的MRSA和VRE的功能和生长。